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Abstract
Psychosis has been hypothesised to be a continuously distributed quantitative phenotype and disorders such as
schizophrenia and bipolar disorder represent its extreme manifestations. Evidence suggests that common genetic variants
play an important role in liability to both schizophrenia and bipolar disorder. Here we tested the hypothesis that these
common variants would also influence psychotic experiences measured dimensionally in adolescents in the general
population. Our aim was to test whether schizophrenia and bipolar disorder polygenic risk scores (PRS), as well as specific
single nucleotide polymorphisms (SNPs) previously identified as risk variants for schizophrenia, were associated with
adolescent dimension-specific psychotic experiences. Self-reported Paranoia, Hallucinations, Cognitive Disorganisation,
Grandiosity, Anhedonia, and Parent-rated Negative Symptoms, as measured by the Specific Psychotic Experiences
Questionnaire (SPEQ), were assessed in a community sample of 2,152 16-year-olds. Polygenic risk scores were calculated
using estimates of the log of odds ratios from the Psychiatric Genomics Consortium GWAS stage-1 mega-analysis of
schizophrenia and bipolar disorder. The polygenic risk analyses yielded no significant associations between schizophrenia
and bipolar disorder PRS and the SPEQ measures. The analyses on the 28 individual SNPs previously associated with
schizophrenia found that two SNPs in TCF4 returned a significant association with the SPEQ Paranoia dimension,
rs17512836 (p-value = 2.5761024) and rs9960767 (p-value = 6.2361024). Replication in an independent sample of 16-year-
olds (N = 3,427) assessed using the Psychotic-Like Symptoms Questionnaire (PLIKS-Q), a composite measure of multiple
positive psychotic experiences, failed to yield significant results. Future research with PRS derived from larger samples, as
well as larger adolescent validation samples, would improve the predictive power to test these hypotheses further. The
challenges of relating adult clinical diagnostic constructs such as schizophrenia to adolescent psychotic experiences at a
genetic level are discussed.
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Introduction
The notion of the psychosis continuum postulates that psychosis
is a continuously distributed quantitative phenotype and disorders
such as schizophrenia and bipolar disorder are its extreme
manifestations [1] (see also [2]). Clinical psychotic symptoms
include (but are not limited to) hallucinations, delusions, cognitive
disorganisation, avolition and anhedonia [3] and can be measured
in the general population [1]. ‘Psychotic experiences’ refers to
these symptoms when assessed as experiences across the full range
of severity in the general population.
Some evidence suggests that early psychotic experiences are a
risk marker for later development of a psychotic disorder [4,5],
although most individuals with psychotic experiences in adoles-
cence do not go on to develop psychotic disorders. High scores on
psychotic experiences in childhood (age 11) were shown to be an
indication of an increased risk of developing a psychotic disorder
later in life (age 26)[4]. However, it is typically not until
adolescence/early adulthood that psychotic symptoms first emerge
[6] and the association between psychotic experiences and a
number of psychiatric disorders strengthens [7]. In a study
conducted by Kelleher et al. [7] prevalence of psychotic
experiences have been shown to decrease over time, from 21%
in early adolescence (11–13 year olds) to 7% in mid-adolescence
(13–16 year olds). In contrast to this, the predictive power of these
psychotic experiences for a number of psychiatric disorders
strengthened with an increase in age. These findings highlight
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the potential value of studying psychotic experiences in mid-
adolescence.
A number of studies have shown that, consistent with adult
schizophrenia, psychotic experiences in adolescence show a
multidimensional factorial structure [8–14]. Although the number
and content of the reported dimensions varies across studies due to
the measures and statistical analyses used, most report at the very
least three dimensions of Positive, Negative and Disorganisation.
Ronald et al. [14] created a quantitative dimension-specific
assessment of positive, cognitive and negative psychotic experi-
ences in adolescence, used in the present study, which was found
to show a six-dimensional structure (Paranoia, Hallucinations,
Cognitive Disorganisation, Grandiosity, Anhedonia and Negative
Symptoms).
In terms of the role of genetic influences on adolescent psychotic
experiences, published twin studies report heritabilities of
psychotic experiences in adolescence to range from 33–57%
depending on dimension [13,15,16]. Heritabilities of the six
dimensions used here ranged from 15–59% (unpublished). The
highest heritabilities were noted for the Negative Symptoms (59%)
and Paranoia (50%) dimensions of psychotic experiences, with the
lowest heritabilities being for Hallucinations (15% for males and
32% for females).
Findings from twin studies suggest that heritabilities of psychotic
disorders are higher than for adolescent psychotic experiences.
Estimates of heritability of both schizophrenia and bipolar
disorder have been shown to be ,80% [17–19] and the bivariate
heritability between the two disorders to be 63% [20]. Common
genetic variants have been shown to play an important role in the
aetiology of both disorders [21]. GWAS that investigate common
single nucleotide polymorphisms (SNPs) have identified several
SNPs in genic and non-genic regions that associate with
schizophrenia risk (reviewed in [22]). A review of these loci [22]
refers to 16 reliably replicated genes/regions that harbour SNPs
that are GWAS significant. A different approach is to use a
polygenic risk score (PRS), which aggregates genome-wide
individual SNPs into a single score. Currently available PRS from
the Psychiatric Genomics Consortium account for 23% of
variation in schizophrenia liability [23] and a much smaller but
significant proportion of ,3% in bipolar disorder liability [24].
PRS can be used as predictors of phenotypes in other samples.
In terms of the genetic relationship between adolescent
psychotic experiences and adult psychotic disorders, currently
the genetic correlation (the degree of overlapping genetic
influences) between adolescent psychotic experiences and clinical
psychosis remains unknown. Here we hypothesise that if genes
influencing risk for liability to psychosis are common in the general
population, and if schizophrenia and bipolar disorder lie on a
phenotypic continuum with psychotic experiences assessed
dimensionally, schizophrenia and bipolar disorder identified
genetic risk variants will also be associated with psychotic
experiences.
Derks et al. [25] were the first to explore the correlation
between the schizophrenia PRS and a dimensional quantitative
measure of schizophrenia symptoms using a case-control design
(N = 314 cases, 148 controls). The authors identified a five-
dimensional structure of psychosis but found no significant
correlation between any dimension and the schizophrenia PRS,
after accounting for case-control status. In contrast to this, Fanous
et al. [26], identified a three-dimensional structure and with a
sample size over twenty-times the magnitude of the previous study,
found schizophrenia negative/disorganised symptom dimension
PRS to be a significant predictor of the PGC schizophrenia case-
control status (r2 = 0.0005, p-value = 0.007). In a separate analysis
the authors also found the negative/disorganised symptom
dimension to be correlated with the PGC schizophrenia PRS (p-
value = 0.03).
To date, one study has explored the association between
psychotic experiences in the general population and schizophrenia
associated genetic risk variants [27]. Psychotic experiences were
assessed as a single categorical construct, where presence of
psychotic experiences was defined as presence of any one of a
number of different positive psychotic experiences. With a sample
of 3,483 individuals assessed when 12 and 18 years old, the authors
reported that on average individuals with psychotic experiences
had higher schizophrenia PRS than those without psychotic
experiences, however the lowest p-value noted did not reach
significance (p-value = 0.134 at pT,0.3). The respective odds ratio
per standard deviation increase in score was 1.08 for the
schizophrenia PRS (calculated based on the results from the
PGC GWAS stage-1 mega-analysis), which the authors regarded
as ‘very weak evidence’ for an association with psychotic
experiences.
The present study adds to this recent work by using both the
schizophrenia and bipolar disorder PRS and testing for their
predictiveness with quantitatively-measured specific psychotic
experiences. The present study includes separate scales for
different types of positive psychotic experiences (paranoia,
hallucinations, grandiosity and delusion), as well as including
cognitive disorganisation and negative psychotic experiences,
which has not been done before. The measures were quantitative
and therefore captured varying severity of manifestation of
psychotic experiences across the population. For example,
paranoia was assessed in terms of how frequently individuals
had paranoid thoughts and items ranged in severity from mild
suspicions that others have an interest in the person all the way to
fears of conspiracies.
In Approach 1, estimates of variance explained in dimension-
specific psychotic experiences in adolescence using schizophrenia
and bipolar disorder PRS(s) were derived. For both the
schizophrenia PRS and the bipolar disorder PRS, we hypothesised
that the PRS would be separately associated with each of the six
dimensions of psychotic experiences. We further hypothesised that
the associations would be positive. It was expected that the PRS
scores would explain a smaller but significant proportion of
variance in adolescent psychotic experiences than they did for the
liability to schizophrenia and bipolar disorder. In Approach 2, 33
selected SNPs from 16 genes/regions previously identified as
influencing risk for diagnosed schizophrenia [22] were tested for
association with quantitative dimension-specific psychotic experi-
ences in adolescents. For each dimension of psychotic experiences
in adolescence, we hypothesised that the selected risk variants
would also be associated with that dimension; we regarded these as
separate hypotheses to be tested individually, without adjustment
for multiplicity. It was expected that while some associations would
be specific to certain dimensions and others would show
pleiotropic effects (i.e. be associated with multiple different types
of psychotic experiences), all associations would be positive. In
Approach 3, a composite schizophrenia SNP score made up of the
selected SNPs from Approach 2 was created to estimate the
variance explained in quantitative dimension-specific psychotic
experiences in adolescence. It was hypothesised that the composite
schizophrenia SNP score would be a significant predictor of
quantitative dimension-specific psychotic experiences in adoles-
cence and that it would explain a small proportion of variance.
Finally, significant findings from Approaches 2 and 3 were tested
for replication in an independent population-based sample of
adolescents (as used in [27]).
Genetic Psychosis Continuum
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Methods
Participants
TEDS, Validation Sample. Individuals who participated in
the current study were drawn from the Twins Early Development
Study (TEDS). TEDS is a longitudinal general population sample
of twins born in England and Wales between 1994 and 1996 [28].
TEDS originally recruited 13,488 families, who responded with a
written consent form.
The current study forms part of the Longitudinal Experiences
And Perceptions (LEAP) project, which investigates the aetiology
of psychotic experiences in adolescence. For the purposes of this
study families were not contacted if they had withdrawn from
TEDS, had never returned any data or had known address
problems. This resulted in 10,874 TEDS families being contacted
and invited to participate in LEAP. Of those, 5,076 (46.7%)
parents and 5,059 (46.5%) twins provided data on quantitative
dimension-specific psychotic experiences at age 16 years
(Mean = 16.32 years; SD = 0.68). Participants were excluded based
on lack of consent at first contact or for the present study, presence
of severe medical disorder(s) including autism spectrum disorder,
lack of zygosity information or experience of severe perinatal
complications.
DNA extracted from buccal cheek swabs from 4,440 children
from TEDS were sent to Affymetrix Santa Clara, California, USA
to be individually genotyped on the AffymetrixGeneChip 6.0 SNP
genotyping platform as part of the TEDS Wellcome Trust Case
Control Consortium 2 (WTCCC2) study of reading and mathe-
matical abilities (see http://www.wtccc.org.uk/ccc2/
wtccc2_studies.shtml). In total, 3,665 samples were successfully
hybridized to AffymetrixGeneChip 6.0 SNP genotyping arrays. Of
the genotyped individuals, 513 were excluded based on one or
more of the following parameters: low call rate or heterozygosity
outliers (377), atypical population ancestry (59), sample duplication
or relatedness to other sample members (83), unusual hybridiza-
tion intensity (9), gender mismatches (13), and having less than
90% of genotypes called identically on the genome-wide array and
Sequenom panel (54) [29]. The final sample of 3,152 individuals
comprised 1,446 males and 1,706 females.
Phenotypic data on psychotic experiences was available for
2,152 of the 3,152 genotyped individuals and limited to those who
were unrelated and of white background. The final sample was
43% male.
ALSPAC, Replication Sample. The Avon Longitudinal
Study of Parents and Children (ALSPAC) [30] core cohort
comprised of 14,541 pregnancies with an expected delivery date
between 1st April 1991 and 31st December 1992 (www.alspac.bris.
ac.uk). When the oldest children of the 14,541 pregnancies were 7
years old additional pregnancies that failed to enrol at first attempt
were added. This resulted in a total sample size of 15,247
pregnancies (15,458 fetuses). Of the 15,458 fetuses, 14,775 were
live births and 14,701 were alive at 1 year of age.
9,912 children from ALSPAC were individually genotyped on
the Illumina HumanHap550 quad genome-wide SNP genotyping
platform. Of the genotyped individuals, some were excluded based
on one or more of the following parameters: incorrect gender
assignments (61), minimal or excessive heterozygosity (375),
disproportionate levels of individual missingness (15), evidence of
cryptic relatedness (1182), and non-European ancestry (734) [31].
The resulting sample comprised 8,365 genotyped individuals.
In total 4,458 children in ALSPAC provided data on psychotic
experiences at age 16 years (M = 16.68 years; SD = 0.24).
Genotypic data was available for 3,427 of those individuals and
limited to unrelated individuals of European ancestry. The final
sample was 42% male. Note that the study website contains details
of all the data that is available through a fully searchable data
dictionary (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/).
Ethical considerations prevented us from publicly depositing the
raw genotypic and phenotypic data but it can be made available in
a suitable form on request from TEDS and ALSPAC.
Ethics Statement
Twins Early Development Study (TEDS) and consent proce-
dure were approved by the Institute of Psychiatry ethics committee
(ref: 05/Q0706/228). The Avon Longitudinal Study of Parents
and Children (ALSPAC) and consent procedure ethical approval
was obtained from the ALSPAC Ethics and Law Committee (IRB
00003312) and the Local Research Ethics Committees. Informed
written consent was obtained for both studies.
Measures
Specific Psychotic Experiences Questionnaire
(SPEQ). In TEDS, dimension-specific psychotic experiences
were assessed using the Specific Psychotic Experiences Question-
naire (SPEQ;[14]). SPEQ includes five self-report subscales
(Paranoia, Hallucinations, Cognitive Disorganisation, Grandiosity
and Anhedonia) and one parent-rated subscale (Parent-rated
Negative Symptoms). SPEQ was based on existing measures that
were adapted specifically for use with adolescents. Items were
placed into separate subscales based on the results of principal
component analysis [14].
Paranoia subscale comprised 15 items rated on a 6-point scale
(not at all; rarely; once a month; once a week; several times a week;
daily) and the total scale ranged from 0 to 75. Hallucinations
subscale of SPEQ comprised nine items measured on a 6-point
scale (not at all; rarely; once a month; several times a week; once a
week; daily) and the total scale ranged from 0 to 45. Cognitive
Disorganisation subscale of SPEQ comprised eleven items measured
on the scale of yes/no responses with the range of total scores from
0 to 11. Grandiosity subscale consisted of eight items measured on a
4-point scale (not at all; somewhat; a great deal; completely) and
the total scale ranged from 0 to 24. Anhedonia subscale consisted of
10-items asking about hedonia rated on a 6-point scale (very false
for me; moderately false for me; slightly false for me; slightly true
for me; moderately true for me; very true for me) and the total
scale ranged from 0 to 50. Anhedonia scale was reversed so that
higher scores signified more Anhedonia. Finally, Parent-reported
Negative Symptoms subscale was made up of 10- items rated on a 4-
point scale (not at all true; somewhat true; mainly true; definitely
true) and the total scale ranged from 0 to 30.
SPEQ subscales show good to excellent internal consistency
(Cronbach’s a ranged from .77 to .93) and test re-test reliability
(r= .65 to .74 across an average 9-month interval; all p,0.001).
The subscales also show good content and construct validity [14].
The derivation of items, and full information on reliability and
validity is also available elsewhere [14].
Psychosis-Like Symptoms measure (PLIKS-Q). In the
replication sample psychotic experiences were assessed using the
Psychosis-Like Symptoms Questionnaire (PLIKS-Q; [32]). The
ALSPAC sample was selected for the purposes of replication of the
findings from the validation sample based on the similar age and
agreement between the PLIKS-Q and SPEQ subscales [14]. The
phenotypic correlations between PLIKS-Q quantitative score and
positive SPEQ subscales were significant, positive, and moderate
to high in magnitude: Hallucinations r= .60, Paranoia r= .48,
Cognitive Disorganisation r= .41, Grandiosity r= .27 (all p,
0.001).
Genetic Psychosis Continuum
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PLIKS-Q quantitative score was computed based on responses
to 10 items rated on a 3-point scale (yes, definitely; yes, maybe; no,
never) that assesses positive psychotic experiences (hallucinations,
delusions and thought interferences). Originally ‘‘no, never’’
responses were coded with the highest numerical value hence
PLIKS-Q total quantitative score was reversed so that higher
scores signified more psychotic-like symptoms. At least 5 responses
were required in order to calculate the total score and the scale
ranged from 1-30.
Statistical Analyses
Phenotypic Analyses
Descriptive statistical analyses were performed in SPSS for
Windows (version 18.0).
Scale Transformation. Due to the moderate skew of the
psychotic experiences scales as measured by SPEQ the data were
transformed using log10(1+variable) formulae for the polygenic risk
analyses. This transformation was selected because it was
considered most suitable for previously conducted analyses on
these measures and to enable direct comparison between analyses
reported elsewhere (unpublished) and variance explained by the
polygenic risk scores (PRS). For comparison polygenic risk
analyses were also performed using the van der Waerden
transformation and the pattern of results remained unchanged.
For the single SNP analyses the psychotic experiences scales as
measured by SPEQ and PLIKS-Q were transformed using van
der Waerden’s transformation [33] to normalise the data, which
works by converting ranked data to the quantiles of the standard
normal distribution.
T-tests. Two-tailed independent t-tests were conducted to
describe mean differences between males and females. Where
Levene’s test was significant, p-values for corrected degrees of
freedom (df) were reported.
Approach 1
Polygenic Risk Scores (PRS). In the current study, Psychi-
atric Genomics Consortium (PGC) schizophrenia [34] and PGC
bipolar disorder [24] stage-1 GWAS mega-analysis full results
were used to create two PRS; one for schizophrenia and one for
bipolar disorder. First, linkage disequilibrium (LD) clumping at p-
value thresholds of 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1.00 was
performed on 943,564 SNPs with high imputation information ($
0.90) in PLINK version 1.07 [35]; http://pngu.mgh.harvard.edu/
purcell/plink/), an open-source whole genome association analysis
toolset. MHC region (26–33 Mb) was excluded based on a
complex LD structure in this region [34]. The procedure
undertaken pruned to r2 = 0.25 within 200 kb windows. The
SNPs in the TEDS sample were also required to have a minor
allele frequency (MAF) .0.02; genotyping .0.90; and Hardy-
Weinberg Equilibrium p.1610-6. PRS were then calculated in
PLINK for each genotyped individual in the TEDS sample by
summing the risk alleles weighted by the estimated log of odds
ratios obtained from the PGC results. PRS were calculated for
eight p-value thresholds (pT). Numbers of SNPs per threshold are
summarised in Tables S1 and S2 in File S1.
Polygenic risk analyses. Linear regression analyses were
performed in SPSS for Windows (version 18.0) with PRS scores as
predictors of the six SPEQ subscales. The significance threshold
for the polygenic risk analyses was set to p,0.05 (one-tailed) as
correlations between different p-value thresholds, pT 0.01 to 1.00,
range from .62 to .99. To control for population stratification,
principal component analyses (PCA) were performed and using
the Tracy-Widom test eight principal components (PCs; p,0.05)
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were identified as covariates and included in the model. Full details
of the PCA analyses can be found in [29].
Approach 2
Selected SNPs for the single SNP analyses. SNPs previ-
ously identified as genetic risk variants for schizophrenia
significant at genome-wide threshold of at least p#5610-8 were
chosen. The initial selection process was informed by the review of
the genome-wide association studies (GWAS) of schizophrenia
findings undertaken by Bergen and Petryshen [22]. Further
examination of the original publications was required in order to
identify the actual SNPs and corresponding risk alleles from the
genes and p-values cited in the review [22]. This resulted in
identification of 10 additional SNPs that met our inclusion criteria
and the final selection of 33 genetic risk variants significantly
associated at p#561028 with schizophrenia. A summary of
selected SNPs is provided in Table S3 in File S1. Three of these
variants were significant based on joint analysis of schizophrenia
and bipolar disorder. These were rs4765905 (CACNA1C;
chromosome 12; p= 7.0161029), rs10994359 (ANK3; chromo-
some 10; p= 2.4561028), and rs2239547 (ITIH3-ITIH4 region;
chromosome 3, p= 7.8361029) [34].
Proxies & Quality Control (QC) in the single SNP analyses.
TEDS, Validation Sample. Six of the 33 selected SNPs were
neither genotyped nor imputed in the validation dataset and a
proxy SNP in linkage disequilibrium (LD) with that candidate SNP
(r2..8; D’ = 1) was identified based on observed patterns in SNAP
[36]. Stringent quality control (QC) as per the genotyped data was
performed. QC filters for the genotypic data required that
genotyping was above 95% complete for each individual and that
each SNP had above 90% genotyping. SNPs that were not in
Hardy-Weinberg Equilibrium were excluded (values below p,
161026), as were SNPs with a MAF of less than 2%. As a result
five of the 33 selected SNPs (rs6913660, rs13194053, rs3800316,
rs6932590, and rs6904071) were excluded from further analyses.
The average call rate per individual post exclusion of the five SNPs
was 99.81%. The results of the QC analyses are summarised in
Table S4 in File S1. QC analyses were performed using PLINK.
Single SNP analyses. Allelic and genotypic association
analyses were undertaken between all SPEQ subscales and the
selected SNPs using the linear regression function in PLINK.
Allelic association analyses were performed using an additive
linear regression model. Genotypic association analyses were
performed using a two degree of freedom joint test of additivity
and dominance deviation. Age and sex were included as covariates
in this study.
The corrected p-value significance threshold using Bonferroni
adjustment was set to p,0.0008 (0.05/(3362); one-tailed), where
0.05 represents nominal significance cut-off, 33 represents the
number of selected SNPs before QC, and 2 represents types of
genetic tests conducted (i.e. allelic and genotypic). The Bonferroni
correction is conservative as it assumes that all tests performed are
independent of one another and could therefore result in
overcorrection and potential false negatives. For this reason, for
significant findings an adaptive permutation approach implement-
ed in PLINK was also employed as it allows the correlational
structure between SNPs to be maintained while manipulating the
genotype-phenotype relationship to generate appropriate empir-
ical significance levels (pEMP). Statistical package R (http://www.r-
project.org/) and LocusZoom [37] were used for graphical
representation of all significant results.
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Approach 3
Schizophrenia composite SNP Score. The composite SNP
score was created by summing unweighted risk alleles (as per the
original publications) of the 28 SNPs of the selected 33 that passed
QC. Linear regressions were performed to estimate variance
explained by the composite SNP score in quantitative psychotic
experiences in the validation sample.
Replication
ALSPAC, Replication Sample. Significant SNPs from Ap-
proach 2 were replicated in the ALSPAC sample. rs17512836 was
not available in the ALSPAC dataset, hence rs17597926 and
rs17527346 were identified as proxies (r2 = . 83; D’ = 1) based on
observed patterns in SNAP [36]. Two proxies rather than one
were selected to ensure that replication was still possible in case of
one of the SNPs failing quality control (QC). Stringent QC was
performed on the SNPs under investigation and the QC filters
were set to match those from the validation sample. Neither SNPs
nor individuals required exclusion based on the set QC filters. The
average call rate per individual was 99.98%. The results of the QC
analyses are summarised in Table S5 in File S1.
Allelic and genotypic association analyses were undertaken
between the PLIKS-Q measure and the selected SNPs using the
linear regression function in PLINK. Age and sex were included as
covariates.
Results
Descriptive Statistics
Descriptive statistics for the SPEQ and PLIKS-Q measures are
summarised in Table 1. SPEQ showed significant phenotypic
mean sex differences across four subscales of psychotic experiences
(p,0.05). Females scored significantly higher than males on
Cognitive Disorganisation and males scored significantly higher
than females on Grandiosity, Anhedonia and Parent-rated
Negative Symptoms (p,0.001). Paranoia and Hallucinations
subscales showed no significant mean differences between sexes
although there was a trend for females to report more experiences.
A summary of results is presented in Table 2. PLIKS-Q
(t(1,3310.21) = 8.53, p,0.001) showed significant mean sex differ-
ences with females scoring higher than males.
Approach 1 results
Descriptive statistics for the schizophrenia PRS and bipolar
disorder PRS are presented in Tables S6 and S7 in File S1. None
of the six dimensions of psychotic experiences (Paranoia,
Hallucinations, Cognitive Disorganisation, Grandiosity, Anhedo-
nia, and Parent-rate Negative Symptoms) showed significant
positive associations with either schizophrenia or bipolar disorder
PRS across all thresholds at p,0.05 (one-tailed). The summary of
results for the schizophrenia and bipolar disorder PRS at pT = 0.5
are presented in Tables 3 and 4 respectively. Full results for all
thresholds per psychotic experiences dimension are presented in
Tables S8 to S19 in File S1.
Approach 2 results
Single SNP analyses. The summary of top results (p,0.05;
one-tailed) for allelic and genotypic association analyses are
presented in Table 5. (Full results can be found under
supplementary materials Table S20 in File S1). A total of
twenty-eight out of thirty-three SNPs previously associated with
schizophrenia were tested for associations with dimension-specific
psychotic experiences. Fourteen out of twenty-eight selected SNPs
showed nominally significant associations at p,0.05 with different
dimension-specific quantitative assessments of psychotic experi-
ences but each failed to meet statistical significance post correction
for multiple testing (p,0.0008; one-tailed). The strongest associ-
ation was observed between the SPEQ Paranoia psychotic
experiences subscale and rs17512836 in TCF4 with C identified
as the risk allele. Both allelic association under an additive model
(b= 4.17; prawdata = 3.86610
25; pEMP = 1.16610
24; b= 0.35;
ptransformeddata = 2.57610
24; pEMP = .001) and genotypic associa-
Figure 1. van der Waerden transformed mean SPEQ Paranoia
scores plotted by rs17512836 genotypes.
doi:10.1371/journal.pone.0094398.g001
Figure 2. van der Waerden transformed mean SPEQ Paranoia
scores plotted by rs9960767 genotypes.
doi:10.1371/journal.pone.0094398.g002
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tion (prawdata = 2.09610
25; pEMP = 0.006; ptransformeddata
= 2.6061024; pEMP = 0.005) were significant for rs17512836
and Paranoia. In addition, association between rs9960767 in
TCF4 and Paranoia was significant in the genotypic test
(prawdata = 4.44610
25; pEMP = 9.33610
24; ptransformeddata =
6.2361024; pEMP = 0.005). Figures 1 and 2 illustrate the above
results in terms of transformed mean scores for the SPEQ
Paranoia psychotic experiences subscale and the three genotypes
per SNP.
The regional association plot in Figure S1 in File S1 provides a
more in-depth view of the flanking region of 400 kb around
rs17512836. The plot illustrates the associated region in the
context of local patterns of LD. Specifically, the figure highlights
four SNPs aside from rs17512836 that have a p#7.5761024. The
strongest associated SNP (rs41437147, p= 8.4761025; two-tailed)
is an imputed SNP, however, two of the four SNPs with a p#
7.5761024 in this region were genotyped. rs35969244 and
rs41515848 with a p= 1.1461024 (two-tailed) and
p= 1.7161024 (two-tailed) respectively. This confirms that the
signal in this region is not based purely on imputed SNPs.
Approach 3 results
The schizophrenia unweighted composite SNP score of 28
SNPs was not a significant predictor of any of the SPEQ psychotic
experiences subscales (p-values ranged from 0.310–0.886). Sum-
mary results of these analyses are presented in Table 6. For
comparison purposes a composite score based on summing of
weighted risk alleles (based on published effect sizes) was also created
but it did not yield any significant results (not shown).
Replication results
Replication of findings from Approach 2 was attempted using
the ALSPAC sample in relation to rs9960767 and rs17512836 that
reached significance in association with the SPEQ Paranoia
subscale in TEDS.
In total three SNPs (two SNPs were used as a proxy for
rs17512836) previously associated with schizophrenia and the
Paranoia SPEQ measure were tested for association with a
quantitative assessment of positive symptoms, PLIKS-Q in the
ALSPAC sample. The analyses did not yield any significant results
at p,0.05. These are summarised in Table 7.
Discussion
To our knowledge, this is the first study to investigate an
association between quantitative dimension-specific psychotic
experiences in adolescence and common genetic variants previ-
ously identified as risk factors for schizophrenia and bipolar
disorder. It joins one other genetic study of psychotic experiences
in adolescence, which reported weak evidence for an association
between categorically defined positive psychotic experiences in
adolescents in the general population and a schizophrenia
polygenic risk score, and no significant associations between
individual schizophrenia-associated SNPs and adolescent psychot-
ic experiences [27].
Approach 1: schizophrenia and bipolar disorder
polygenic risk analyses
The schizophrenia and bipolar disorder polygenic risk score
analyses, using the full results of the PGC stage-1 GWAS mega-
analysis [24,34], yielded no significant positive associations with
dimension-specific psychotic experiences.
There are several plausible explanations for our lack of findings.
First, it is possible that the schizophrenia and bipolar disorder PRS
are significant predictors of other dimensions of psychotic
experiences (e.g. mania) that were not assessed in the current
study. However the SPEQ measure provided a fairly comprehen-
sive assessment of specific positive, cognitive and negative
psychotic experiences. Second, the phenotypes from the PGC
data are based on clinical samples; as such these are known to have
certain biases, such as inflated comorbidity, and decreased global
functioning, compared to community derived samples. These
different sample biases may act to decrease the ability to identify
genetic associations between them. Third, PRS used in the current
study were calculated based on results from case-control genome-
wide association studies (GWAS) and not dimension-specific
schizophrenia or bipolar disorder symptoms. It is possible that
there would be greater predictive power on specific psychotic
experiences from a PRS that was specific to each symptom
grouping within schizophrenia or bipolar disorder. This is further
supported by the evidence from a number of genetic association
studies and a twin study, which show that symptom variation
within clinical psychosis is partly influenced by ‘modifier
genes’(genes that influence clinical features of a disease but not
its liability) [38,39], which might also influence adolescent
psychotic experiences. However, because schizophrenia can
include each of the psychotic experiences used in this study, it
was still hypothesised that each specific psychotic experience
would be predicted by the schizophrenia PRS. Fourth, evidence
from one twin study suggests that while psychotic experiences are
moderately stable across adolescence, new genetic influences
become involved across age [13]. It is therefore plausible that the
SNPs associated with schizophrenia and bipolar disorder that were
tested in the current study are not yet involved at age 16. The
higher prevalence of ‘confirmed’ psychotic experiences in adoles-
Table 6. Results of regression analysis with the schizophrenia composite SNP score as a predictor of the SPEQ measures (adjusted
for sex and age and performed on the transformed data).
b SE t-Stat p-value C.I. R2
Paranoia 0.13 0.54 0.35 .730 20.592–0.845 .002
Hallucinations 20.35 0.34 21.02 .310 21.025–0.33 .001
Cognitive Disorganisation 20.34 0.35 20.96 .337 21.026–0.35 .036
Grandiosity 20.14 0.35 20.38 .701 20.826–0.556 .021
Anhedonia 20.12 0.36 20.34 .737 20.816–0.577 .057
Parent-rated Negative Symptoms 20.05 0.33 20.14 .886 20.694–0.599 .015
Note: b, Beta; SE, standard error; C.I., confidence interval.
doi:10.1371/journal.pone.0094398.t006
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cence than of psychotic disorders in adults suggests some psychotic
experiences dissipate in individuals over time [27]. However, our
hypothesis for an association between loci associated with
schizophrenia and adolescent psychotic experiences is supported
by phenotypic associations reported between earlier psychotic
experiences and adult psychosis [4,5]. Fifth, the genetic correlation
between adolescent psychotic experiences and adult schizophrenia
is not known because no twin data or genome-wide complex trait
analysis (GCTA) [40,41] findings on this bivariate relationship
have been reported. It is not known the degree to which the
relationship between adolescent psychotic experiences and psy-
chotic disorders is influenced by genetic or environmental
influences. Finally, as further PRS become available that have
greater accuracy of prediction of their own phenotype (e.g. of
schizophrenia or bipolar disorder), they will offer greater power for
testing predictions about genetic relationships with related
phenotypes such as psychotic experiences in younger individuals
[42].
Approaches 2 and 3: single SNP analyses and
schizophrenia composite score
The single SNP analyses performed in Approach 2 of our study
yielded two significant associations between previously identified
loci for schizophrenia liability and Paranoia, one of the dimension-
specific psychotic experiences. These signals were not replicated in
an independent sample measured on a cumulative scale of positive
psychotic experiences (not on Paranoia specifically). It is notewor-
thy that although not replicated, both SNPs (rs17512836 and
rs9960767; r2 = 0.44, D’ = 0.95) identified in the validation sample
were located in an intron of TFC4. It is possible that replication of
Approach 2 findings in an independent sample failed because of
the difference in measures used. We note that the two measures
show a good agreement [14] but unlike SPEQ, PLIKS-Q (the
measure of psychotic experiences used in the replication sample) is
not a dimension-specific measure. Instead it includes a variety of
positive psychotic experiences within a single scale.
In our data we observed a trend towards different SNPs showing
stronger associations with some of the dimensions of psychotic
experiences; although not replicated, these findings are consistent
with genetic studies of schizophrenia symptoms. These suggest that
some schizophrenia liability genes are more strongly associated
with some of the schizophrenia symptoms than with others [43–
46]. For example, SNPs in COMT have been shown to associate
more strongly with manic symptoms [43] whilst SNPs in DTNBP1
with negative symptoms [45].
In the current study, when the 28 selected SNPs were
aggregated into a composite schizophrenia SNP score in Approach
3, they yielded no significant results for any of the dimensions.
Limitations
The results of our study should be interpreted in light of some
limitations. First, it would have been ideal to have a mania
subscale included in the measurement. Second, the measure used
in the replication sample did not allow for specific psychotic
experiences to be assessed individually. Third, self and parent
reports of psychotic experiences are likely to include specific forms
of measurement error due to circumstances of individuals
misunderstanding the nature of the phenomena being asked
about, and a lack of adjustment for cultural norms. Fourth, our
sample size may have been a limiting factor in detection of the
potential positive associations. It is noted that the one other study
similar to this one in its aims had a validation sample that was
double the size of this one and they were only just able to detect
‘very weak effects’ [27].
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Conclusions
The current study provides the first empirical test of whether
aggregated common variants and single SNPs associated with
schizophrenia and bipolar disorder are also predictive of
dimension-specific psychotic experiences in adolescence. In order
to improve on this existing work, future studies should aim to
increase the sample sizes assessed on psychotic experiences and
employ future polygenic risk scores that explain larger proportions
of the liability to schizophrenia and bipolar disorder. Taking into
account the transient nature of some psychotic experiences in
adolescence is a challenge. Uncovering the genetic aetiology of
psychotic experiences in adolescence could bring us a step closer to
understanding the common pathway that takes people from
experiencing psychotic experiences in adolescence to the point of
developing clinically-recognised psychotic disorders. In future
work, polygenic risk scores will hopefully offer the opportunity to
predict, albeit in a limited and probabilistic way, groups of people
at risk of complex heritable psychiatric illness [47].
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